Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

AIMS: To evaluate 0.75 mg of dulaglutide, a once‐weekly glucagon‐like peptide‐1 receptor agonist, compared with once‐daily insulin glargine for glycaemic control in Japanese patients with type 2 diabetes (T2D). METHODS: In this phase III, randomized, open‐label, parallel‐group, 26‐week study, 361 pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, E., Inagaki, N., Tanizawa, Y., Oura, T., Takeuchi, M., Imaoka, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042081/
https://www.ncbi.nlm.nih.gov/pubmed/26179754
http://dx.doi.org/10.1111/dom.12540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042081/
https://www.ncbi.nlm.nih.gov/pubmed/26179754
http://dx.doi.org/10.1111/dom.12540

Ejemplares similares